Asset Details
Do you wish to reserve the book?
Tuning the release rate of rilpivirine from PLGA-based in situ forming implants
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tuning the release rate of rilpivirine from PLGA-based in situ forming implants
Do you wish to request the book?
Tuning the release rate of rilpivirine from PLGA-based in situ forming implants
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tuning the release rate of rilpivirine from PLGA-based in situ forming implants
2023
Overview
In situ forming implants (ISFI) based on poly(lactic-
co
-glycolic acid) (PLGA) are promising long-acting injectable depots for the treatment of human immunodeficiency virus-1 infection. One of the key parameters of depot formulations is the drug release rate which is critical for the development of optimal dosing regimens. The goal of this research is to investigate the most significant factors affecting the rilpivirine release rate from PLGA-based ISFI, including the influence of the polymer content and structure (i.e. molecular weights, lactide/glycolide ratios, and chemistry of the terminal group). Thus, the use of a low molecular weight PLGA reduces the burst-effect from 17.5 to 4.7% of the drug content and enables continuous release of rilpivirine over the period of 42 days. At the same time, a more hydrophobic PLGA with a lactide/glycolide ratio of 75/25 and a terminal ester group affects to a greater extent the rilpivirine release rate in the third phase of the release process, when destruction of the polymer matrix starts. The rilpivirine release profile from the implant, formed by using a 30% (w/w) solution of PLGA with a higher content of lactic acid (75:25) and a terminal ester group, is similar to the dissolution profile of rilpivirine nanocrystals (Rekambis
®
).
Graphical abstract
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
